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Abstract. Molecular-targeted therapy was recommended for 
the systemic therapy of renal cell cancer (RCC) in the RCC 
guidelines, but these guidelines do not address the order of 
administration of the multiple presently available agents. There 
are several aspects that remain unknown regarding the optimal 
administration order and combination of molecular-targeted 
drugs. Until the optimal treatment sequence is determined by 
clinical trials, treatment individualization is required for each 
patient based on patient and disease characteristics. We herein 
investigate 12 cases of RCC patients who received axitinib. 
Axitinib was used as the first‑line drug in 4 cases, second‑line in 
5 cases, third-line in 1 case and as a fourth-line drug in 2 cases. 
Partial response (PR) was observed in 4 cases (30%) and stable 
disease in 4 cases (30%) during axitinib treatment, with an 
overall response rate of 60%. The duration of PR ranged from 6 
to 19 months. Based on our cases, axitinib exhibited reasonable 
therapeutic efficacy as first‑ as well as second‑line treatment. 
However, more cases are required to draw firm conclusions.
Introduction
Molecular-targeted therapy was recommended for the 
systemic therapy of renal cell cancer (RCC) in the 2011 
Japanese Urological Association RCC guidelines (1,2); 
however, these guidelines do not address the order of admin-
istration of presently available multiple agents. The European 
Association of Urology guidelines recommend either sunitinib 
or everolimus as first‑line therapy, and sorafenib or everolimus 
as second-line therapy, although there are several aspects that 
remain unknown regarding the optimal administration order 
and combination of the multiple molecular-targeted drugs (3). 
At the 2015 ASCO annual meeting, the results of a comparison 
test of sunitinib→everolimus vs. everolimus→sunitinib 
were reported, indicating that the median survival rates 
were 29.5 and 22.2 months, respectively, concluding that 
sunitinib→everolimus was more effective (4,5).
Until clinical trials determine the optimal treatment 
sequence, treatment individualization is required for each 
patient based on patient and disease characteristics. In this 
study, we investigated 12 cases of renal cancer in which 
axitinib had been administered.
Patients and methods
Case series. A total of 12 patients who were diagnosed with 
RCC between 2005 and 2011 were reviewed (Table I). Approval 
was obtained from the Ethics Committee of our institution at 
the commencement of the study. The patients included 9 men 
and 3 women, with a mean age of 66 years (range, 58-79 years). 
Axitinib was used as a first‑line drug in 4 cases, second‑line 
in 5 cases, third-line in 1 case and as a fourth-line drug in 
2 cases. Partial response (PR) was observed in 4 cases (30%) 
and stable disease in 4 cases (30%) during axitinib treatment, 
with an overall response rate of 60%. The duration of PR 
ranged from 6 to 19 months.
Of the 4 PR cases, the case 1 patient had received axitinib 
as first‑line therapy, and he had not received any other molec-
ular-targeted drugs; in 2 PR cases, axitinib was administered as 
second-line treatment; in the remaining PR case, axitinib had 
been followed by panitumab, with which a clinical response 
was achieved.
Case reports. Case 6 was a 61-year-old male patient. At the 
initial visit, an 8-cm mass was identified, extending from 
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the posterior aspect of the upper left lung to the chest wall, 
infiltrating the ribs and the Th1 vertebral body, with partial 
compression of the spinal cord. The computed tomography 
(CT) scan revealed a 3-cm tumor in the inferior pole of the 
Figure 1. Case 6: Computed tomography revealed a 3-cm tumor in the inferior pole of the right kidney (left panel, pretreatment; right panel, post-treatment).
Figure 2. Case 6: Computed tomography revealed that, although the renal lesion was reduced, the bone metastatic lesion exhibited progression (left panel, 
pretreatment; right panel, post-treatment).
Table I. Summary of the investigated 12 cases. 
Case Age,      PR duration, 
no. years Sex Drugs (sequence) Metastastic sites Effectiveness months
  1.  79 Male A Lung, adrenal PR 6
  2.  59 Male Su→A→E Lung, bone PD 
  3.  73 Male Su→A Lung, liver PR 9
  4.  69 Male Su→A Kidney, lung, pancreas PR 6
  5. 47 Male INF→Su→A Lung, lymph nodes SD 
  6. 61 Male A→P Bone, pleural cavity PR 19
  7. 58 Female Su→A Lung, lymph nodes, brain, bone PD
  8.  76 Female Su→A Liver SD 
  9.  76 Female INF→So→UFT→A Lung, lymph nodes SD 
10.  64 Male A→E→INF→Su →So Adrenal, pancreas PD 
11. 67 Male GC→GDC→E→A Lung, liver, bone SD→PD 8 (SD, collecting
      ductal carcinoma)
12.  63 Male A Bone, lung PD
A, axitinib; Su, sunitinib; E, everolimus, INF, interferon; So, sorafenib; P, pazopanib; GC, gemcitabine and carboplatin; GDC, gemcitabine, 
docetaxel and carboplatin; PR, partial response; PD, progressive disease; SD, stable disease.
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right kidney (Fig. 1). CT-guided tumor biopsy of the lung 
mass revealed RCC metastasis. Axitinib was administered at 
10 mg/day; after 10 days, the dose was increased to 12 mg/day, 
and to 14 mg/day 2 weeks later. At the time of admission to the 
hospital the patient was bedridden. Following intensive reha-
bilitation, the patient was able to use a wheelchair and even to 
leave his house. The treatment was continued on an outpatient 
basis. However, due to progression of metastatic bone disease 
(Fig. 2), the patient was readmitted to the hospital. He currently 
remains alive and is on pazopanib treatment.
We encountered one case of collecting duct carci-
noma, which is a type of RCC refractory to cytotoxic and 
molecular-targeted therapy. However, case 11, a 67-year-old 
male patient, achieved PR. The patient visited our hospital 
complaining of hematuria. Based on the results of the pathology, 
he was diagnosed with renal collecting duct carcinoma with 
renal hilar lymph node metastasis. After 4 months, the patient 
underwent left nephrectomy and the subsequent pathological 
diagnosis was pT3, ly1, v1, INFβ, pN2. Four weeks after the 
operation, the patient was started on adjuvant GC chemo-
therapy (gemcitabine 1,200 mg and cisplatin 300 mg) (6) and 
completed four cycles. Six months postoperatively, multiple 
pulmonary metastases were identified on CT, and metastasis to 
the right pelvic bone was identified by bone scintigraphy. GDC 
chemotherapy (gemcitabine 1,200 mg, docetaxel 80 mg and 
cisplatin 300 mg) was initiated 4 weeks later (7). The results 
of the CT conducted on June 20, 2012 confirmed peritoneal 
dissemination, progression of multiple lung metastases and 
revealed metastatic liver disease. Two months later the patient 
was administered 10 mg everolimus. After administration of 
everolimus for 3 months, the blood sugar level was found to be 
high, which was considered to be an adverse event (AE) and 
the drug was discontinued, followed by normalization of the 
patient's blood sugar levels, after which time everolimus was 
resumed at a reduced dose of 5 mg. At the 8-month follow-up 
the patient remained progression-free, which is unusually long 
for renal collecting duct cancer.
Discussion
Based on our cases, axitinib demonstrated reasonable therapeutic 
efficacy as first‑ as well as second‑line treatment. However, to 
draw a firm conclusion, more cases must be accumulated.
Procopio et al reviewed 13 cases of renal collecting duct 
carcinoma. Renal collecting duct carcinoma patients (median 
age, 57 years) comprise 3.4% of all metastatic RCC (mRCC) 
patients, with a median survival time of 4 months, with only 
3 cases having survived 6-33 months (8-11). The disease‑specific 
survival of our patient (case 11) was 13 months from the time of 
the appearance of metastases. In a study on the administration 
of sunitinib, axitinib, sorafenib, interferon and temsirolimus 
as first‑line drugs in 4,736 mRCC cases, a reduction ratio of 
>7-8% of the tumor was associated with a relatively good 
prognosis (12). Moreover, in a study on the combined use 
of tyrosine kinase inhibitors (TKIs) and mammalian target 
of rapamycin inhibitors in 153 cases of metastatic clear cell 
RCC (ccRCC), comparing the combined use of lenvatinib 
and everolimus with the use of lenvatinib alone and with the 
use of everolimus alone, achieved a survival of 13.1, 7.5 and 
8.5 months, respectively, indicating that combination therapy 
was superior to single-agent treatment (13). Furthermore, in a 
study of 108 cases of non-ccRCC, survival with sunitinib was 
8.3 months and that with everolimus 5.6 months, indicating 
that sunitinib was superior; however, for poor-risk RCC, 
survival was 4.0 and 6.1 months for sunitinib and everolimus, 
respectively, indicating that everolimus was better for poor-risk 
cases (14).
A study of the programmed cell death protein-1 (PD-1) 
antibodies for RCC was also conducted (15-17). The therapeutic 
effects of pazopanib and sunitinib in RCC cases expressing PD-1 
were significantly inferior to the PD‑1 low‑expressing cases, 
and the median survival time was also shorter (18). Nivolumab 
(PD-1-inhibiting antibodies) was investigated in 91 cases, and it 
was effective in programmed death-ligand-1 (PD-L1)-positive 
as well as -negative cases (based on immunostaining of cancer 
cells). While a 71% 1-year survival was attained by both positive 
and negative cases, the 2-year survival rates were 64 and 48%, 
respectively (19). In addition, the mPFS of the cases in whom 
anti-PD-1 treatment had not been effective and in whom TKIs 
had been administered was 6.9 months, indicating that it may 
be safely administered (20). Immunostaining for PD-L1 was 
positive in 51% of spindle cell cancer cases, whereas 100% of 
the cases that contained a ccRCC component were positive (18). 
However, due to the fact that only 17% of the ccRCCs that did 
not contain a spindle cell carcinoma component were PD-L1 
positive, there is a possibility that PD-1 antibodies are effec-
tive in spindle cell cancer, which has poor prognosis (21). A 
study to predict therapeutic effect based on immunostaining for 
PD-L1 of tumor cells has been conducted. However, cases were 
successfully treated irrespective of positive or negative immu-
nostaining; thus, no conclusion was reached at that time (22). 
Moreover, it is considered that the more gene mutations the 
cancer cells harbour, the more successful the immunotherapy. 
Further research on immune therapy that includes PD-L1 anti-
bodies is expected in the near future.
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